Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)

Today we announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with chemotherapy was well tolerated with encouraging and durable antitumor activity for first-line treatment of advanced HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) in the ongoing Phase 2 clinical study. A poster with an updated data […]

Zymeworks Presents Preclinical Data on TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference

Today we presented preclinical data associated with our TLR7 ISACs technology. The poster presentation titled “Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)” shows the potential of using novel purine-based TLR7 agonists as payloads for ISACs. ISACs consist of antibodies conjugated to immune stimulants and are designed to induce antitumor immune […]